Home
Resources
Publications
Complete Clinical and Functional Recovery Following Low-Dose Methotrexate Related Paraparesis in a Patient With Compound c.1298A>C AND c.677C>T MTHFR Polymorphism: A Case Report

Complete Clinical and Functional Recovery Following Low-Dose Methotrexate Related Paraparesis in a Patient With Compound c.1298A>C AND c.677C>T MTHFR Polymorphism: A Case Report

Gianantonio Saviola, Lul Abdi-Ali, Silvano Sacco, Laura Comini, Katrin Plewnia, Maja Rossi, Alfredo Orrico

Medicine (Baltimore). 2018 Dec;97(49):e13350.

PMID: 30544400

Abstract:

Rationale:
The mechanisms of action of MTX (methotrexate) in the treatment of RA (rheumatoid arthritis) and PsA (psoriatic arthritis) is related to its antifolic activity, due to the high affinity for enzymes that require folate cofactors as dihydrofolate reductase and to the anti-inflammatory activity derivated from the inhibition of thymidylate synthetase that leads to the over-production of adenosine.
Patient concerns:
Our patient was a 41-year-old female, affected by PsA in treatment since 2 years with low-dose methylprednisolone and low-dose subcutaneous MTX. The treatment was effective. The patient subacutely developed a severe paraparesis with impossibility of gait or standing without aid and was admitted to a Neurology Department where the cause of the paraparesis was not clear in spite of accurate radiological neurophysiologic and laboratory tests. Therefore, she was admitted in a rehabilitation unit.
Diagnosis and interventions:
Paraparesis in PsA patient in treatment with methotrexate. MTX toxicity was hypothesized; therefore the drug was discontinued while i.m. folic acid and cyanocobalamin were administered for 20 days. The diagnosis was clinical, based on neurological examination (paraparesis) and on the chronic use of MTX (hypothesis of toxicity).
Outcomes:
The patient obtained a complete resolution of paraparesis. Genetic analyses showed associated a compound heterozygosity for the c.1298A>C and c.677C>T variants of methylenetetrahydrofolate reductase (MTHFR) gene.
Lessons:
Neurological side effects of MTX are uncommon. In literature no previous case of MTX induced paraparesis in patients treated with low-dose MTX for chronic arthritis has been described. The association between the gene polymorphisms of MTHFR (c.1298A>C and c.677C>T) and MTX toxicity in arthritis patients is confirmed. The case also confirms that folates are a precious antidote of MTX toxicity.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP2410937	Methotrexate Related Compound C		2410-93-7	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: